Clinical Trial Update: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating IPI-504 for advanced dedifferentiated liposarcoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Dedifferentiated Liposarcoma | Phase 2 | Status: WITHDRAWN